Support for You and Your Patients

Teva Support Solutions^® provides comprehensive access and
affordability support for you and your patients

Teva Support Solutions® 1-844-838-2211

$0 Medication costs per dose and Administration costs per treatment. Up to $10,000 per year

*The CINQAIR Cost Support Program helps commercially insured individuals in the United States (including the United States territories) who are prescribed CINQAIR pay for their eligible out-of-pocket costs for the drug and for administration of the drug, including co-pays, co-insurance, and deductibles.

Persons residing in a state that does NOT allow financial assistance for the administration of the drug may ONLY be eligible to receive out-of-pocket cost support for the drug.

The Program does not cover the costs of physician office visits or evaluations, blood work or other testing, or transportation. Eligible individuals must have commercial insurance for CINQAIR. Uninsured and cash-paying patients are NOT eligible for this Program, nor are individuals with commercial insurance coverage that does not provide coverage for CINQAIR. ^†

^†Talk to your representative for complete Terms and Conditions.

Call Teva Support Solutions ^®for information on specialty pharmacies that can help with home infusion

Prescription and Service Request Form

Complete this 1-page form to enroll your patients in Teva Support Solutions^®.

Product Acquisition

Learn how CINQAIR may be ordered/dispensed.

Access & Affordability

Find information on a variety of services, including Benefits Verification, Prior Authorization Support, and Administration Location Assistance.

Training & Education

Learn about the personalized education and training offered by Clinical Nurse Educators.

Teva Support Solutions^®

Offers support for patients throughout their CINQAIR treatment journey

Learn more by visiting www.TevaSupportSolutions.com

Teva Support Solutions^®

Access & Affordability

Training & Educations

Rx Product Acquisition

INDICATIONS AND USAGE

CINQAIR is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype.

Limitations of Use: CINQAIR is not indicated for:

treatment of other eosinophilic conditions
relief of acute bronchospasm or status asthmaticus

IMPORTANT SAFETY INFORMATION

WARNING: ANAPHYLAXIS

Anaphylaxis, occurring in 0.3% of CINQAIR patients in clinical studies, was reported as early as the second dose.
As anaphylaxis can be life-threatening, observe patients after CINQAIR administration and be prepared to manage anaphylaxis. Discontinue CINQAIR immediately if there are signs or symptoms of anaphylaxis.

IMPORTANT SAFETY INFORMATION (continued)

CONTRAINDICATIONS

CINQAIR is contraindicated in patients hypersensitive to reslizumab or its excipients.

WARNINGS AND PRECAUTIONS

Acute Asthma Symptoms or Deteriorating Disease: Do not use CINQAIR to treat acute asthma symptoms or exacerbations, acute bronchospasms, or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after CINQAIR initiation.
Malignancy: In clinical studies, 6/1028 (0.6%) of CINQAIR patients had at least 1 malignant neoplasm vs 2/730 (0.3%) of placebo patients. The malignancies were diverse without clustering of any tissue type. Most malignancies were diagnosed within 6 months of CINQAIR use.
Reduction of Corticosteroid Dosage: Reduction of maintenance corticosteroids following use of CINQAIR was not assessed. Do not abruptly discontinue systemic or inhaled corticosteroids upon CINQAIR initiation. Reductions in corticosteroid dose, if appropriate, should be gradual and supervised by a physician and may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroids.
Parasitic (Helminth) Infection: Eosinophils may be involved in immunological response to helminth infections. Treat patients with preexisting helminth infections before initiating CINQAIR. If patients become infected while receiving CINQAIR and do not respond to anti-helminth treatment, discontinue CINQAIR until infection resolves.

ADVERSE REACTIONS

The most common adverse reaction (incidence greater than or equal to 2%) includes oropharyngeal pain.

Please see Full Prescribing Information, including Boxed WARNING .